RMC-6236 is under clinical development by Revolution Medicines and currently in Phase I for Gynecological Cancer. According to GlobalData, Phase I drugs for Gynecological Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RMC-6236’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RMC-6236 overview

RMC-6236 is under development for the treatment of solid tumor, colorectal cancer, pancreatic ductal adenocarcinoma cancer, melanoma, gynecological cancer and non-small cell lung cancer. It is administered through oral route. The drug candidate is a RAS-selective, tri-complex inhibitor. It acts by targeting the GTP bound form of KRAS (G12V, G12D, G13C, G13D, Q61H), NRAS (Q61X) and HRAS mutants.

Revolution Medicines overview

Revolution Medicines is a clinical-stage precision oncology company that discovers and develops medicines and therapies for cancer patients. The company product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. Its other product includes RMC-4630, RMC-5552 and SOS1. Revolution Medicines also provides a research and development pipeline comprising RAS(ON) inhibitors that bind directly to RAS variants. The company partners with pharmaceutical companies and healthcare organizations for its drug development activities. Revolution Medicines is headquartered in Redwood City, California, the US.

For a complete picture of RMC-6236’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.